Home > Healthcare > Medical Devices > Therapeutic Devices > Wearable Injectors Market
Wearable Injectors Market size was worth USD 8 billion in 2022 and will progress at over 13.5% CAGR from 2023 to 2032. The industry demand is fueled by the growing prevalence of chronic diseases, including immunological disorders, diabetes, cardiovascular diseases, and cancer, among others.
For instance, as per the International Diabetes Federation, around 537 million people were suffering from diabetes in 2021, which is further projected to exceed 643 million by 2030. Patients suffering from several chronic conditions often require long-term treatment, and wearable injectors offer a convenient and less invasive way to administer medication.
Wearable injectors are drug-delivery devices that adhere to the body and automatically deliver set doses of medication to the patient at optimal times. They offer many benefits to the user and drug manufacturers, including precise dosing, ease of use, adherence, and tracking capabilities. Moreover, the increasing number of government initiatives for the treatment and prevention of chronic ailments, such as cancer, diabetes, and cardiovascular diseases, in homecare facilities to combat the rising chronic disease burden will boost the industry progress.
Despite a positive outlook for the wearable injectors market, the preference for alternative drug delivery systems is negatively impacting industry revenue. The ability to improve patient compliance and convenience offered by alternative systems is restraining product utilization. High adoption of traditional drug delivery methods, such as intravenous injections and oral medications due to a dearth of awareness associated with advanced delivery systems is affecting overall market demand. However, growing awareness regarding advanced non-invasive drug delivery methods for long-term treatment among several nations is anticipated to accelerate the market trends.
Report Attribute | Details |
---|---|
Base Year: | 2022 |
Wearable Injectors Market Size in 2022: | USD 8 Billion |
Forecast Period: | 2023 to 2032 |
Forecast Period 2023 to 2032 CAGR: | 13.7% |
2032 Value Projection: | USD 27 Billion |
Historical Data for: | 2018-2032 |
No. of Pages: | 270 |
Tables, Charts & Figures: | 465 |
Segments covered: | Type, Device Type, Technology, Application, End User, and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
The COVID-19 pandemic disrupted many ongoing clinical trials as well as R&D efforts. With lockdowns and social distancing measures in place, there was a surge in the demand for home healthcare solutions. The coronavirus outbreak necessitated minimizing in-person healthcare visits and reducing the burden on healthcare facilities. Wearable injectors offered a convenient and safe option for patients to receive necessary treatments without visiting healthcare facilities requiring regular injections, such as those with chronic conditions like diabetes or autoimmune diseases.
The expanding geriatric population is a chief factor driving the demand for healthcare services and medication, which is fostering the business outlook. Wearable injectors cater to the needs of elderly patients who may have difficulties with traditional injection methods. The ability to self-administer medication at home promotes independence and improves the quality of life for older individuals. Furthermore, a growing emphasis on personalized medicine, where treatments are tailored to individual patients based on their unique characteristics and needs is complementing industry development.
In terms of type, the wearable injectors market is segmented as on body and off body. The on-body segment size is speculated to reach more than USD 15 billion in revenue by 2032. Continuous improvements in wearable injector design, specs, and technology offer many advantages, including an ergonomic design, compact device, and water resistance, among others, which are favorably influencing patient preference for on-body devices. Additionally, the incorporation of digital technology into on-body wearable injectors enables patients to track their health data in real-time at home and manage their drug consumption.
With respect to application, the wearable injectors market is segmented as oncology, cardiovascular diseases, diabetes, autoimmune diseases, and others. The diabetes segment will be valued at USD 9 billion by 2032. The high incidence of diabetes worldwide and the increased convenience and effectiveness of wearable injectors in the treatment of diabetes will promote product adoption. Moreover, the positive inclination of healthcare professionals owing to numerous advantages for managing diabetes, such as better patient outcomes and adherence is likely to propel wearable injectors use in clinical settings.
Regionally, the North America wearable injectors market is estimated to grow at more than 13.5% CAGR from 2023 to 2032, attributed to the high prevalence of diabetes, which will create greater demand for wearable injectors for enhanced effectiveness and convenience in diabetes disease management. Moreover, the rising number of healthcare facilities that incorporate advanced equipment for chronic disabilities and illnesses is propelling the demand for wearable injectors in the region.
The top players involved in the wearable injectors industry report are
These companies are engaging in strategic partnerships and mergers, along with new product launches, to stay ahead in the industry.
Click here to Buy Section of this Report
Market Size, By Type
Market Size, By Device
Market Size, By Technology
Market Size, By Application
Market Size, By End User
The above information is provided for the following regions and countries: